Key result
Gyro C1E3 pump avoids downstream thromboembolism in calves despite internal thrombi forming after 2 days.
Why the study?
Is the mass production model of the Gyro C1E3 centrifugal blood pump safe and feasible for long-term cardiac assist in an ex vivo calf model?
Population
5 healthy calves
Design
Preclinical
Follow-up
up to 30 days
Authors
Loading...
Supports Gyro C1E3 feasibility in calves; leaves open anticoagulation optimization and human translation.
Is the mass production model of the Gyro C1E3 centrifugal blood pump safe and feasible for long-term cardiac assist in an ex vivo calf model?
The Gyro C1E3 centrifugal blood pump is capable of long-term assist circulation in a calf model, though higher anticoagulation targets (ACT >250 sec) are recommended after 2 days to prevent intra-pump thrombosis.
Takano et al. (2000) studied Long-term cardiac assist (n=5). Gyro C1E3 centrifugal blood pump was evaluated on Thrombus formation and bearing deformation. The Gyro C1E3 centrifugal blood pump caused no downstream thromboembolism in 5 calves over up to 30 days, though thrombi formed inside pump heads after 2 days when ACT was 200-250 seconds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: